Trials / Completed
CompletedNCT03369301
The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency
Effect of Subcutaneous Immunoglobulin (IgSC) Gammanorm® on the Distribution of IgG Subclasses and on the Humoral Immunity of Patients With Secondary Immunodeficiency.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (actual)
- Sponsor
- Octapharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with Myeloma or CLL with severe secondary hypogammaglobinemia and recurrent infections will be included in this study; for whom an IgSC treatment was prescribed. The IgSC prescription will be the decision of the treating physician. Patient care and follow up will be performed according to the current clinical practice and the recommendations of HAS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gammanorm | Gammanorm given per standard of care |
| DRUG | Other Subcutaneous Immunoglobulins | Other Subcutaneous Immunoglobulins given per standard of care |
Timeline
- Start date
- 2017-09-25
- Primary completion
- 2019-11-22
- Completion
- 2019-11-22
- First posted
- 2017-12-12
- Last updated
- 2022-03-02
Locations
6 sites across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03369301. Inclusion in this directory is not an endorsement.